Improving 24-hour Blood Pressure in Obstructive Sleep Apnea

University of British Columbia

Status and phase: Withdrawn; Early Phase 1

Conditions: Obstructive Sleep Apnea

Treatments: Other: Microcrystalline Cellulose; Dietary Supplement: Alpha-Lipoic Acid 600mg; Device: Continuous Positive Airway Pressure CPAP; Drug: Telmisartan 80mg

Study type: Interventional

Funder types: Other

Identifiers

NCT04021550

H18-03130

Details and patient eligibility

About

This study examines the combined effects of an angiotensin receptor blocker (ARB), antioxidant supplementation, and continuous positive airway pressure (CPAP) therapy on the lowering of 24-hour blood pressure in persons with moderate to severe Obstructive Sleep Apnea (OSA). All participants will undergo CPAP therapy as prescribed by their doctor; however, half of the participants will receive the combined ARB and antioxidant treatment while the other half of the participants will receive a placebo.

Full description

OSA is a sleep disorder characterized by repetitive collapses (apneas) or partial collapses (hypopneas) of the upper airway. These airway obstructions result in intermittent reductions in arterial oxygen saturation (hypoxia), which causes a reflexive increase in sympathetic activation and systemic vasoconstriction. Resumption of breathing results in transient surges in blood pressure (BP) that can reach as high as 240/130 mm/Hg.

OSA effects up to 24% of the adult population and evidence suggests a causal relationship between OSA and cardiovascular disease (CVD) development. While the exact mechanisms are unknown, data from animal and human models suggest that exposure to chronic intermittent hypoxia (IH) plays a significant role in the pathogenesis of cardiovascular comorbidity. Persons with OSA exhibit increased daytime sympathetic activity, markers of oxidative stress, and vasoactive hormones, particularly angiotensin II, that contribute to systemic vasoconstriction. These factors contribute to early endothelial dysfunction and contribute to sustained elevations in BP.

While CPAP is the gold standard OSA treatment, adherence rates are low and evidence suggests that treatment does not reduce the rates of CVD in large population-based studies.

Telmisartan is a receptor blocker for angiotensin II and not only has BP lowering effects, but also has unique anti-inflammatory properties and beneficial influences on endothelial function. The addition of an antioxidant supplement may increase the reactive oxygen species scavenging capacity and, in combination with ARB treatment, may provide more robust effects on BP in persons with OSA.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Apnea/Hypopnea Index (AHI) greater than/equal to 15 events per hour of sleep
• No prior use of CPAP
• Body mass index less than 30kg/m2
• Does not take ARBs or angiotensin converting enzyme inhibitors for blood pressure control
• Females of childbearing potential on an effective or highly effective means of contraception

Exclusion criteria

• Prescribed and/or taking the following medications: diuretics (including potassium-sparing diuretics), Digoxin, lithium salts, and/or nonsteroidal anti-inflammatory drugs
• Over the counter supplements that affect the cardiovascular system, such as fish oils, vitamins, or other antioxidants
• History of heart failure
• History of myocardial infarction
• History of coronary artery disease
• History of stroke
• History of diabetes mellitus
• History of impaired renal function
• History of chronic obstructive pulmonary disease
• History of asthma
• History of central sleep apnea
• Smoked within the past year
• Hypotensive (Systolic blood pressure (SBP) <90 mmHg and diastolic blood pressure (DBP) <60 mmHg)
• Females who do not have a means of contraception, are pregnant, planning to become pregnant, and/or are breast-feeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

0 participants in 2 patient groups, including a placebo group

Combined Treatment

Experimental group

Description:

Subjects will be given 80 mg/day Telmisartan + 600 mg/day Alpha-Lipoic Acid. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.

Treatment:

Dietary Supplement: Alpha-Lipoic Acid 600mg

Drug: Telmisartan 80mg

Device: Continuous Positive Airway Pressure CPAP

Placebo Control

Placebo Comparator group

Description:

Subjects will be given placebo capsules. Subjects will also be prescribed CPAP therapy by their physician. Subjects will be instructed to use their CPAP device according to their physician's guidelines.

Treatment:

Other: Microcrystalline Cellulose

Device: Continuous Positive Airway Pressure CPAP